Top Markets
#1 Akedo Akedo +59.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.41%
#4 Velvet Velvet +39.92%
#5 Black Phoenix Black Phoenix +34.56%
#6 Ο„emplar Ο„emplar +23.53%
#7 Ribbita by Virtuals Ribbita by Virtuals +17.77%
#8 Cross Cross +15.77%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.57%
#10 Bitway Bitway +15.46%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Entheon Biomedical Corp. Entheon Biomedical Corp.

Entheon Biomedical Corp.

ENBI
Rank in Stocks #38407
Entheon Biomedical Corp. functions as a biotechnology firm focused on the... Entheon Biomedical Corp. functions as a biotechnology firm focused on the research and development of novel pharmaceuticals. The company is actively involved in pioneering and introducing to market psychedelic therapeutic products, specifically those derived from N,N-dimethyltryptamine (DMT), with the aim of combating addiction and various substance use disorders. Its services are provided to medical doctors, healthcare facilities, and accredited psychiatrists across Canada, the United States, and the European Union. Entheon Biomedical Corp.'s primary operations are based in Vancouver, Canada.
Share Price
$0.0719818
Last synced: 2026-01-15
Market Cap
$997.59K
Change (1 day)
-0.09%
Change (1 year)
4.67%
Country
CA
Trade Entheon Biomedical Corp. (ENBI)

Category

Healthcare
P/E ratio for Entheon Biomedical Corp. (ENBI)
P/E ratio as of 2026 TTM: 0
According to Entheon Biomedical Corp. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Entheon Biomedical Corp. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.